Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

Abbott, Medtronic go head-to-head at ADA conference - Page 2 of 9 - Medical Design and Outsourcing

FreeStyle Libre Continuous Glucose Monitoring

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

FreeStyle Libre 2 Continuous Glucose Monitor

FreeStyle Libre 2 System (CGM)

FreeStyle Libre 2 Continuous Glucose Monitor

FreeStyle Libre 2 Continuous Glucose Monitor

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

Healthy Living Now Providing the Abbott Freestyle Libre to Medicare Members — Healthy Living Medical Supply

FreeStyle Libre 2 System (CGM)

FreeStyle Libre 2 Continuous Glucose Monitor

FreeStyle Libre 2 System

Freestyle Libre 2 - Continuous Glucose Monitoring System